Table 1.
Characteristic | SCP (n = 234) |
SCP Plus APN (n = 238) |
P* | ||
---|---|---|---|---|---|
No. | % | No. | % | ||
Recommended COG screening frequency† | .40 | ||||
Every 2 years | 51 | 21.8 | 53 | 22.3 | |
Every 5 years | 43 | 18.4 | 33 | 13.9 | |
Every year | 140 | 59.8 | 152 | 63.9 | |
Sex† | .59 | ||||
Female | 122 | 52.1 | 130 | 54.6 | |
Male | 112 | 47.9 | 108 | 45.4 | |
Age at random assignment, years† | .94 | ||||
≥ 30 | 202 | 86.3 | 206 | 86.6 | |
< 30 | 32 | 13.7 | 32 | 13.4 | |
Race | .89 | ||||
White non-Hispanic | 208 | 88.9 | 210 | 88.2 | |
Black | 3 | 1.3 | 3 | 1.3 | |
Other | 21 | 9.0 | 25 | 10.5 | |
Unknown | 2 | 0.9 | 0 | 0.0 | |
Education level | .86 | ||||
≤ High school graduate | 25 | 10.7 | 21 | 8.8 | |
Post–high school training/some college | 65 | 27.8 | 70 | 29.4 | |
College graduate | 92 | 39.3 | 90 | 37.8 | |
Postgraduate | 52 | 22.2 | 57 | 23.9 | |
Household income | .56 | ||||
< $20,000 | 16 | 6.8 | 20 | 8.4 | |
$20,000 to $60,000 | 74 | 31.6 | 65 | 27.3 | |
≥ $60,000 | 138 | 59.0 | 144 | 60.5 | |
Unknown | 6 | 2.6 | 9 | 3.8 | |
Health insurance | .71 | ||||
Yes or Canadian | 210 | 89.7 | 215 | 90.3 | |
No | 22 | 9.4 | 20 | 8.4 | |
Unknown | 2 | 0.9 | 3 | 1.3 | |
Diagnosis | .08 | ||||
Bone cancer | 39 | 16.7 | 44 | 18.5 | |
CNS tumor | 1 | 0.4 | 0 | 0.0 | |
Hodgkin lymphoma | 43 | 18.4 | 37 | 15.5 | |
Kidney (Wilms) | 27 | 11.5 | 11 | 4.6 | |
Leukemia | 77 | 32.9 | 81 | 34.0 | |
Non-Hodgkin lymphoma | 20 | 8.5 | 28 | 11.8 | |
Neuroblastoma | 11 | 4.7 | 10 | 4.2 | |
Soft tissue sarcoma | 16 | 6.8 | 27 | 11.3 | |
Age at cancer diagnosis, years | .86 | ||||
0-4 | 65 | 27.8 | 60 | 25.2 | |
5-9 | 47 | 20.1 | 52 | 21.8 | |
10-14 | 57 | 24.4 | 63 | 26.5 | |
15-20 | 65 | 27.8 | 63 | 26.5 | |
Years since diagnosis | .37 | ||||
≤ 28 | 104 | 44.4 | 96 | 40.3 | |
> 28 | 130 | 55.6 | 142 | 59.7 | |
Years since last survey | .79 | ||||
1 | 8 | 3.4 | 12 | 5.0 | |
2 | 100 | 42.7 | 97 | 40.8 | |
3 | 118 | 50.4 | 119 | 50.0 | |
4 | 8 | 3.4 | 10 | 4.2 | |
Chemotherapy | .38 | ||||
Yes | 211 | 90.2 | 220 | 92.4 | |
No | 23 | 9.8 | 18 | 7.6 | |
Radiation therapy | .58 | ||||
Yes | 157 | 67.1 | 166 | 69.7 | |
No | 76 | 32.5 | 72 | 30.3 | |
Unknown | 1 | 0.4 | 0 | 0.0 | |
Both chemotherapy and radiation therapy | .30 | ||||
Yes | 134 | 57.3 | 148 | 62.2 | |
No | 99 | 42.3 | 90 | 37.8 | |
Unknown | 1 | 0.4 | 0 | 0.0 | |
Chest irradiation | .66 | ||||
Yes | 65 | 27.8 | 63 | 26.5 | |
No | 163 | 69.7 | 173 | 72.7 | |
Unknown | 6 | 2.6 | 2 | 0.8 | |
Brain irradiation | .10 | ||||
Yes | 48 | 20.5 | 65 | 27.3 | |
No | 180 | 76.9 | 171 | 71.8 | |
Unknown | 6 | 2.6 | 2 | 0.8 | |
Alkylating agent | .25 | ||||
Yes | 164 | 70.1 | 178 | 74.8 | |
No | 70 | 29.9 | 60 | 25.2 | |
Anthracycline | .35 | ||||
Yes | 189 | 80.8 | 200 | 84.0 | |
No | 45 | 19.2 | 38 | 16.0 | |
Surgery | .99 | ||||
Yes | 189 | 80.8 | 193 | 81.1 | |
No | 44 | 18.8 | 45 | 18.9 | |
Unknown | 1 | 0.4 | 0 | 0.0 | |
Amputation | .68 | ||||
Yes | 19 | 8.1 | 22 | 9.2 | |
No | 214 | 91.5 | 216 | 90.8 | |
Unknown | 1 | 0.4 | 0 | 0.0 | |
Completed cardiomyopathy screening form | .54 | ||||
Yes | 206 | 88.0 | 205 | 86.1 | |
No | 28 | 12.0 | 33 | 13.9 | |
Grade 1 to 4 chronic condition at any time | .35 | ||||
No | 44 | 18.8 | 37 | 15.5 | |
Yes | 190 | 81.2 | 201 | 84.5 | |
Grade 1 to 4 chronic condition at any time | .74 | ||||
No | 150 | 64.1 | 156 | 65.5 | |
Yes | 84 | 35.9 | 82 | 34.5 | |
≥ Two grade 3 to 4 chronic conditions at any time | .52 | ||||
No | 209 | 89.3 | 208 | 87.4 | |
Yes | 25 | 10.7 | 30 | 12.6 | |
Health status | .86 | ||||
Excellent/very good/good | 219 | 93.6 | 219 | 92.0 | |
Fair/poor | 15 | 6.4 | 17 | 7.1 | |
Unknown | 0 | 0.0 | 2 | 0.8 |
Abbreviations: APN, advanced-practice nurse; COG, Children's Oncology Group; SCP, survivorship care plan.
P value based on χ2 comparison among participants with known value of covariate. Fisher's exact test used when cell count < 5.
Stratification factors for randomization.